WO2015073509A3 - Biomarker for melk activity and methods of using same - Google Patents

Biomarker for melk activity and methods of using same Download PDF

Info

Publication number
WO2015073509A3
WO2015073509A3 PCT/US2014/065173 US2014065173W WO2015073509A3 WO 2015073509 A3 WO2015073509 A3 WO 2015073509A3 US 2014065173 W US2014065173 W US 2014065173W WO 2015073509 A3 WO2015073509 A3 WO 2015073509A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
biomarker
melk
same
ortholog
Prior art date
Application number
PCT/US2014/065173
Other languages
French (fr)
Other versions
WO2015073509A8 (en
WO2015073509A2 (en
Inventor
Jean Zhao
Yubao Wang
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Priority to US15/034,955 priority Critical patent/US10254283B2/en
Priority to EP14862279.8A priority patent/EP3068930A4/en
Priority to AU2014348780A priority patent/AU2014348780B2/en
Priority to CN201480072848.3A priority patent/CN106232878A/en
Priority to CA2928464A priority patent/CA2928464A1/en
Publication of WO2015073509A2 publication Critical patent/WO2015073509A2/en
Publication of WO2015073509A3 publication Critical patent/WO2015073509A3/en
Publication of WO2015073509A8 publication Critical patent/WO2015073509A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The methods of the present invention, relate to the surprising determination that the level of phosphorylation of position 406 (e.g., a serine residue.) of human eukaryotic initiation factor 4B (cIF4B), or a corresponding phosphorylatafale amino acid of an ortholog thereof, serves as a bhiraarker for MELK enzymatic (e.g., kinase) and/or oncogenic activity. The methods of the present invention further ceiate to the surprising determination that the level of phosphorylation of position 3 (e.g., a threonine residue) and/or position 10 (e.g., a serine residue) and/or position 11 (e.g., a threonine residue) of human Historic M3, or a corresponding phosphorylatable amino acid of an ortholog thereof, also serves as a biomarker for MELK enzymatic (e.g., kinase) and/or oncogenic activity.
PCT/US2014/065173 2013-11-12 2014-11-12 Biomarker for melk activity and methods of using same WO2015073509A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US15/034,955 US10254283B2 (en) 2013-11-12 2014-11-12 Biomarker for MELK activity and methods of using same
EP14862279.8A EP3068930A4 (en) 2013-11-12 2014-11-12 Biomarker for melk activity and methods of using same
AU2014348780A AU2014348780B2 (en) 2013-11-12 2014-11-12 Biomarker for MELK activity and methods of using same
CN201480072848.3A CN106232878A (en) 2013-11-12 2014-11-12 The biomarker of MELK activity and the method that uses it
CA2928464A CA2928464A1 (en) 2013-11-12 2014-11-12 Biomarker for melk activity and methods of using same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361902877P 2013-11-12 2013-11-12
US61/902,877 2013-11-12
US201461954046P 2014-03-17 2014-03-17
US61/954,046 2014-03-17
US61/954,048 2014-03-17

Publications (3)

Publication Number Publication Date
WO2015073509A2 WO2015073509A2 (en) 2015-05-21
WO2015073509A3 true WO2015073509A3 (en) 2016-01-14
WO2015073509A8 WO2015073509A8 (en) 2016-05-26

Family

ID=55867713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/065173 WO2015073509A2 (en) 2013-11-12 2014-11-12 Biomarker for melk activity and methods of using same

Country Status (5)

Country Link
EP (1) EP3068930A4 (en)
CN (1) CN106232878A (en)
AU (1) AU2014348780B2 (en)
CA (1) CA2928464A1 (en)
WO (1) WO2015073509A2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1651956A4 (en) * 2003-08-14 2008-08-20 Exelixis Inc Melks as modifiers of the rac pathway and methods of use
EP2574929A1 (en) * 2011-09-28 2013-04-03 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Marker in diagnosing prostate cancer (PC)
CN103173527A (en) * 2011-12-22 2013-06-26 上海生物芯片有限公司 Application of MELK gene
KR101920109B1 (en) * 2012-01-19 2018-11-19 온코세라피 사이언스 가부시키가이샤 1,5-naphthyridine derivatives and melk inhibitors containing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP3068930A4 *
YANG ET AL.: "elF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes.", CANCER RES., vol. 73, no. 15, 7 June 2013 (2013-06-07), pages 4898 - 908, XP055343890 *

Also Published As

Publication number Publication date
EP3068930A2 (en) 2016-09-21
AU2014348780A1 (en) 2016-06-02
CN106232878A (en) 2016-12-14
WO2015073509A8 (en) 2016-05-26
CA2928464A1 (en) 2015-05-21
AU2014348780A8 (en) 2016-06-30
WO2015073509A2 (en) 2015-05-21
AU2014348780B2 (en) 2018-12-13
EP3068930A4 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
TN2018000276A1 (en) Inhibitors of receptor-interacting protein kinase 1.
IL254919A0 (en) Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same
PH12016502177A1 (en) Processes of preparing a jak1 inhibitor and new forms thereto
IL277006A (en) Cd73 inhibitors
PL3317269T3 (en) Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
WO2016055777A3 (en) Modified enzymes
SG11202002192QA (en) Restoration of t cell activity via the cd39/cd73 axis
IL304348A (en) Cd73 inhibitors
NZ725917A (en) Novel polymerase-i inhibitors, uses and methods for making them
MX2022010755A (en) Kinase inhibitors and uses thereof.
ZA201802059B (en) Assay for the diagnosis of dermatophytosis
WO2016079110A3 (en) Use of enzyme for cleaning
MX2017008280A (en) Process of making cenicriviroc and related analogs.
MA39824A (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
WO2015185672A3 (en) New markers for the assessment of an increased risk for mortality
IL248567A0 (en) Use of known compounds as d-amino acid oxidase inhibitors
WO2015022077A8 (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
WO2016069542A3 (en) Lactone compounds and methods of making and using same
HRP20190286T1 (en) Processes for the preparation of compounds, such as 3-arylbutanals, useful in the synthesis of medetomidine
EP3677263A4 (en) Composition for decreasing serum uric acid level
MY188420A (en) Crystalline forms of (s)-afoxolaner
EP3532044A4 (en) Hdac inhibitor compositions for reactivation of the x chromosome
WO2015073509A8 (en) Biomarker for melk activity and methods of using same
PL3983005T3 (en) Combination of markers for predicting the response to vx-001

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14862279

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2928464

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15034955

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014348780

Country of ref document: AU

Date of ref document: 20141112

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014862279

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014862279

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14862279

Country of ref document: EP

Kind code of ref document: A2